Subject: CIIX Updates Investors on Upcoming IPO of Wholly Owned Subsidiary

SCV Client Spotlight
BY READING THIS EMAIL YOU CERTIFY YOU HAVE READ THE DISCLAIMER BELOW AND THE FULL DISCLAIMER PROVIDED THROUGH A LINK AT THE END OF THIS EMAIL. This is a paid advertisement., Inc. is not responsible or held liable for the information in the press releases issued by the companies in these emails. Please always do your own due diligence.
Facebook Twitter YouTube
CIIX Updates Investors on Upcoming IPO of Wholly Owned Subsidiary
Hot Stock to WatchHot Stock to Watch

Company: (OTCQB: CIIX)


Price: 0.505

Change (%): - 0.005 (0.98)

Volume: 6,168
CIIX Chart, Inc. Engages Boustead Securities, LLC for Planned IPO of its Wholly Owned Subsidiary, CBD Biotech

SAN GABRIEL, California and SHANGHAI, China, December 27, 2018 /PRNewswire/ -, Inc. (OTCQB: CIIX) (“CIIX” or the “Company”), a financial information website for Chinese-speaking investors, today announced that it has retained Boustead Securities, LLC as underwriter for the planned Initial Public Offering (“IPO”) of its wholly owned foreign enterprise, CBD Biotech Co. Ltd. (“CBD Biotech”), concurrently with a listing on a national securities exchange.

Mr. Warren Wang, Founder, CEO and Chairman of Chinese, commented, “This is part of a series of actions we have put into place to execute on our strategic plan to spin-out CBD Biotech. Additionally, we believe that listing on a national exchange speaks to the quality of CBD Biotech, will provide us with market visibility and access to capital, and further support our growth strategy. We look forward to working with Boustead Securities as IPO sponsor and underwriter.”

Boustead Securities’ Dan McClory, Managing Director, Head of China, and Head of Equity Capital Markets, stated, “We believe CBD Biotech can potentially gain a first mover advantage in the Chinese CBD market, and could be well received in the public markets. Boustead looks forward to supporting CBD Biotech’s growth mission with capital through the planned IPO and national exchange listing.”

Continue Reading

SmallCapVoice (SCV) is an electronic publication. Information sources for our profiles include, but are not limited to, online research, member suggestions, magazines, newspapers, analyst suggestions, publicly available material information provided by the profiled company, press releases and similar sources. This communication is not an offer to sell or a recommendation that you buy or sell any security. SCV holds no securities licenses and is not qualified to provide investment advice. We are compensated for these advertisements by the profiled companies. You should not use this newsletter as the sole basis for any investment decision. While all investments involve risk, microcap stocks are among the most risky. Many microcap companies have no proven track record. You should only invest in microcap companies if you can afford to lose your entire investment. You should consult a qualified, licensed financial advisor or stock broker before making any decisions to invest in the securities of any company that is described in these profiles. These profiles are paid advertisements. Although we have a reasonable belief that the information in each profile is accurate, we cannot guarantee that this information, which originates from third parties, is accurate. We do not have the resources to confirm the accuracy of all information obtained from third parties. It is important for you to verify all information by your own independent research. You are receiving this message because you have agreed to receive emails from You may opt out of our distribution list at any time by clicking on the “unsubscribe” link below. Link to full disclosure about compensation paid to, Inc. by companies featured on our website or in our e-mail communications.

About Penny Stocks